Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EHT102 in Pediatric Patients With Biallelic hOTOF Mutations
NCT07288580Phase 2Recruiting
- Sponsor
- Euhearing Therapeutics
- Start
- Apr 2026
- Primary completion
- Jun 2028
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of EHT102 in congenital hearing loss, sponsored by Euhearing Therapeutics. Started Apr 2026; status: recruiting.
02
Drugs
EHT102
03
Conditions
congenital hearing loss
Beyond the preview
Go deeper on NCT07288580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07288580.